# Quiz 1-Class of Case

1. A patient was diagnosed with breast cancer at another facility. She then came to your facility for an FNA of an enlarged lymph node. The FNA was positive for metastatic breast cancer. The patient went elsewhere for surgery and adjuvant treatment.
	1. 00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
	2. 14 Initial diagnosis at reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
	3. 21 Initial diagnosis elsewhere AND part of first course treatment or a decision not to treat was done at the reporting facility
	4. **30 Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere)**
2. A patient is diagnosed with lung cancer at your facility. The patient does not return for staging work-up or treatment consultation. You do not know if the patient went elsewhere for additional work-up or treatment. The class of case would be...
	1. 00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
	2. **10 Initial diagnosis at the reporting facility or in a staff physician’s office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS**
	3. 12 Initial diagnosis in staff physician’s office AND all first course treatment or a decision not to treat was done at the reporting facility
	4. 30 Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere)
3. A patient was diagnosed at your facility and then referred to a non-staff medical oncologist. The Medical Oncologist did not recommend treatment due to co-morbid disease. The patient did not seek any additional consultations and did not get any treatment. The patient was eventually admitted to a hospice facility. What is the Class of Case for this patient?
	1. **00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere**
	2. 11 Initial in a staff physician’s office AND part of first course treatment or a decision not to treat was at the reporting facility, NOS
	3. 14 Initial diagnosis at reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
	4. 30 Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere)
4. A patient was diagnosed with cancer in a physician’s office by a physician with staff privileges at Hospital A and Hospital B. The patient underwent surgical resection at Hospital A and chemotherapy at Hospital B. Class of case for Hospital B is …
	1. 00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
	2. **11- Initial diagnosis in staff physician’s office AND part of first course treatment was done at the reporting facility**
	3. 12- Initial diagnosis in staff physician’s office AND all of first course treatment was done at the reporting facility
	4. 21- Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility
5. Class of case 00 includes which of the following scenarios?
	1. Diagnosed at the reporting facility and treatment given in the staff physician's office
	2. Diagnosed in a staff physician’s office and treated in the same staff physician's office
	3. Diagnosed at the reporting facility and treated in a non-staff physician’s office
	4. Diagnosed at the reporting facility. Patient never returned. It is unknown if the patient received treatment
	5. All of the above
	6. **A and C only**
	7. A, B and C only

Match the situation to the correct Class of Case from the choices below (Use each value once):

a) Patient diagnosed with breast cancer at local clinic and travels to reporting facility for surgery.

b) Patient dies in ED at reporting facility. Subsequent autopsy reveals previously undiagnosed pancreatic cancer.

c) Diagnostic radiology at reporting facility identifies tumor in posterior fossa. Patient undergoes craniotomy at another facility for removal of hemangioblastoma.

d) Diagnosed with cancer via a biopsy at the reporting facility, the patient does not return for further workup and/or treatment. No other information available.

e) Person in town on business is admitted for an unrelated issue and receives one of their chemotherapy treatments while an inpatient.

f) Patient has suspicious polyp removed during colonoscopy which is positive for in situ adenocarcinoma.

g) Following a diagnosis of pancreatic cancer at their local hospital, the patient has a Whipple procedure at the reporting facility. Returns home for adjuvant chemotherapy.

h) Patient with history of LUL lobectomy presents two years later with recurrent Large cell neuroendocrine carcinoma.

00 \_C\_ 10 \_D\_ 14 \_F\_ 20 \_A\_

21 \_G\_ 31 \_E\_ 32 \_H\_ 38 \_B\_

# Quiz 2-Terminology

1. Write the standard abbreviation or symbol as documented in NAACCR Recommended Abbreviations for Abstractors
	1. Alcohol ETOH
	2. Well Differentiated WD, WELL DIFF, or W/DIFF
	3. Hispanic Female HF
	4. Consistent With C/W
	5. Date of Birth DOB
	6. Right Upper Outer Quadrant RUOQ
	7. No Evidence of Disease NED
	8. Positive + or POS
2. Match the prefix/suffix with the best definition

|  |  |  |
| --- | --- | --- |
| Peri | D | A: excessive, above normal |
| Para | E | B: pain |
| Oma | C | C: tumor |
| Sub | H | D: around or about |
| Hyper | A | E: alongside of, near |
| Dys | G | F: of or pertaining to the wrist |
| Dynia | B | G: abnormal |
| Carp(o) | F | H: under, below |

1. Match the standard abbreviation with the definition

|  |  |  |
| --- | --- | --- |
| @ | F | A: Squamous Cell Carcinoma |
| SLNBX | D | B: Differentiated/differential |
| SQCC | A | C: Hormone Replacement Therapy |
| DCIS | H | D: Sentinel Lymph Node Biopsy |
| DIFF | B | E: Postoperative(-ly) |
| HRT | C | F: At |
| POST | G | G: Posterior |
| POST OP | E | H: Ductal Carcinoma In-Situ |

1. Match the organ with the regional lymph nodes.

|  |  |  |
| --- | --- | --- |
| Lung | E | A: Hepatic  |
| Breast | C | B: Retroperitoneal |
| Larynx | D | C: Intramammary |
| Ovary | F | D: Cervical |
| Stomach | G | E: Hilar |
| Liver | A | F: Pelvic |
| Kidney | B | G: Pyloric |

1. Match the organ with the surgical procedure

|  |  |  |
| --- | --- | --- |
| Tongue | C | A: Anterior temporal lobectomy |
| Breast | E | B: Gastrectomy |
| Lung | F | C: Glossectomy |
| Stomach | B | D: Cystectomy |
| Uterus | G | E: Lumpectomy |
| Bladder | D | F: Pneumonectomy |
| Brain | A | G: Hysterectomy |

Match the Parts of the Body where Gastrointestinal Tumors Form to the letter:



|  |  |
| --- | --- |
| C | Ileum |
| F | Duodenum |
| E | Appendix |
| G | Small intestine |
| H | Rectum |
| A | Colon |
| D | Jejunum |
| B | Stomach |

1. A paracentesis is done to…
	1. **Remove fluid from the abdomen**
	2. Evaluate lymph nodes for malignancy
	3. To help control the side effects of chemotherapy
	4. To amplify the effectiveness of radiation
2. A malignant pleural effusion is most likely related to
	1. A CNS primary
	2. A prostate primary
	3. A breast primary
	4. **A lung primary**
3. Which of the following correctly describes the layers of the stomach wall?
	1. **Mucosa, Submucosa, Muscle Layer, Subserosa, Serosa**
	2. Visceral peritoneum, blood vessel, serosa, Muscle layer, Submucosa
	3. Epidermis, Dermis, Subcutaneous Tissue
	4. None of the above
4. Which of the following is the point at which the trachea divides into the right and left mainstem bronchus?
5. Lingula
6. Hilum
7. **Carina**
8. Mediastinum
9. The supraglottis is within the:
10. Esophagus
11. **Larynx**
12. Pharynx
13. Stomach
14. What carries oxygenated blood from the lungs to the heart?
15. Capillaries
16. Lymphatic vessels
17. Pulmonary arteries
18. **Pulmonary veins**
19. The parietal peritoneum:
20. Covers portions of the lung
21. **Lines the abdominal and pelvic walls**
22. Covers all of the abdominal organs
23. Connects the colon to the abdominal wall
24. The site of origin of a leiomyosarcoma is most likely the:
25. Cervix
26. Endometrium
27. **Myometrium**
28. Ovary
29. Subcarinal lymph nodes are regional nodes for:
30. **Lung**
31. Pancreas
32. Rectum
33. Stomach

# Quiz 3-Casefinding

Circle Yes if the situation is reportable and No if the situation is not reportable according to STORE. Assume all cases diagnosed in 2018 or later.

* 1. Yes No Serous Cystadenoma with borderline malignancy of the ovary
	2. Yes **No** Polycythemia, NOS
	3. **Yes** No Carcinoma in situ of the cervix with micro invasion
	4. Yes No MRI of the brain: Lesion in the occipital lobe of the brain.
	5. Yes No MRI of the brain: A small pituitary tumor
	6. Yes No Cytology from a paracentesis: probable malignant ascites.
	7. Yes No Suspicious breast mass, suspicious for malignancy
	8. Yes No Potentially malignant lung mass

Indicate whether the following diagnoses would be reportable, based on the terms provided:

Yes No

a) Tumor in RUL, very likely malignant \_\_\_ \_X\_

b) Nodule in L lobe of prostate suspicious for malignancy \_X\_ \_\_\_

c) IVP reveals potentially malignant nodule on R kidney \_\_\_ \_X\_

d) Urine cytology consistent with urothelial cell carcinoma \_\_\_ \_X\_

e) Suspicious neoplasm in R occipital lobe \_X\_ \_\_\_

f) 2cm Hypoechoic irreg. mass L breast @ 10:00 worrisome for ca. \_\_\_ \_X\_

g) Peripheral blood: findings are consistent with B Lymphoblastic lymphoma \_X\_ \_\_\_

h) Multiple Lesions across back, chest, arms, face, and legs most likely Kaposi sarcoma \_X\_ \_\_\_

1. Which one of the following best describes the sequence number?

1. The order in which a primary tumor was accessioned into the facility’s database
2. **The order in which a primary tumor is discovered in relation to the total number of reportable  tumors the patient has been diagnosed with**
3. The number of malignant tumors over the lifetime of the patient
4. The total number of tumors reportable to the CoC
5. A patient was diagnosed and treated at your facility three years ago with a carcinoma in situ of the cervix. Your facility collects carcinoma in situ of the cervix as a reportable by agreement case. The patient now presents with a new diagnosis of lung cancer and a benign brain tumor. Assuming the patient has no additional reportable malignancies assign a sequence to each primary.
	1. Carcinoma in situ of the cervix \_\_ \_\_ 01
	2. Lung \_\_ \_\_ 02
	3. Benign brain tumor \_\_ \_\_ 60
6. A patient was diagnosed and treated at your facility three years ago with a meningioma (9530/0) over the left temporal lobe. The patient now presents with a new diagnosis of adenocarcinoma of the lung (8140/3) and a neurofibroma (9540/0) in the central nervous system. Assuming the patient has no additional reportable malignancies assign a sequence (sequence hospital) to each primary as it would look today.
	1. Meningioma \_\_ \_\_ 61
	2. Lung \_\_ \_\_ 00
	3. Neurofibroma \_\_ \_\_ 62
7. The resource that defines all diagnoses and types of cases that should be included and excluded from the registry database is called the:
	1. Suspense system
	2. **Reportable list**
	3. Class of case
	4. Abstract
8. Casefinding is the systematic method of identifying what?
	1. The number of cases seen by the hospital each year
	2. **All eligible cases that are to be included in the cancer registry database**
	3. All cases that were diagnosed in the pathology department
	4. The number of patients that are treated in the hospital
	5. The number of admissions as identified on the HIM disease indices
9. Which of the following statements INCORRECTLY describes a case eligibility rule?
	1. **Juvenile astrocytoma diagnosed in 2023 should be recorded in the registry database with a behavior code of /3**
	2. Malignant primary skin cancers (primary site code of C44.) with a histology code in the range of 8000-8110 are not required to be reported by the CoC as of 1/1/2003
	3. Carcinoma in situ of the cervix (CIS) is not required by the CoC
	4. Basal Cell carcinoma of the skin is not required by the CoC.
10. Which of the following cases are reportable to the CoC?
	1. Melanoma (8720/3) of the skin of the arm (C44.6)
	2. Squamous cell carcinoma (8070/3) of the anus (C21.0)
	3. Subependyoma (9383/1) of the frontal lobe (C71.1)
	4. Carcinoid (8420/3) of the appendix (C18.1)
	5. **All of the above**
11. Which of the following is an analytic case?
	1. **The patient is diagnosed at your facility and sent elsewhere for treatment**
	2. The patient receives treatment at your facility for a recurrence. There is no information on first course of treatment available.
	3. The diagnosis is established by death certificate only
	4. Your facility manages or treats a recurrence or progression of disease after the reference date
	5. Cancer is diagnosed at autopsy. Prior to autopsy there was no suspicion or diagnosis of cancer.
12. Which of the following is a non-analytic case?
	1. The patient is diagnosed at your facility, but it is unknown whether or not treatment was recommended or administered.
	2. The patient is diagnosed at the facility and is referred elsewhere for treatment.
	3. **The patient was diagnosed and treated for a malignancy elsewhere and presents to your facility for treatment for recurrence or progression of disease.**
	4. The patient is diagnosed elsewhere, and all or part of the first course of treatment is performed at the facility.

# Quiz 4-Manuals

A patient was diagnosed with pancreatic cancer on 7/13/2020. You are abstracting the case today (3/2/2023). Which version of the following manuals would you use?

1. STORE Manual
	1. **STORE 2018**

***A or D is acceptable. Technically, you should go to the most current version of the STM. The instructions would tell you to go to 2007 rules. However, if you already knew to go to the 2007 rules, there is no need to check the current version.***

* 1. STORE 2021
	2. STORE 2022
	3. STORE 2023
1. Solid Tumor Manual
	1. **2007 Multiple Primary and Histology Manual**
	2. Solid Tumor Manual (July 2019 Update)
	3. Solid Tumor Manual (September 2021 Update)
	4. **Solid Tumor Manual (2023 Update (most current version))**

***I don’t know the answer… I hope you do. My guess would be you would use the manual in effect the year the case was diagnosed. The answer is probably A or B.***

1. Your State, regional, provincial, or territorial manual
	1. 2018 version
	2. 2020 version
	3. 2021 version
	4. 2023 version
	5. Other

A patient was diagnosed with medulloblastoma on 1/15/23. You are abstracting the case today (3/2/2023). Which version of the following manuals would you use?

1. Summary Stage 2018
	1. Version 2.0 (released January 2021)

***Medulloblastoma is a new schema for 2023. There is a new chapter in the Summary Stage 2018 manual. Medulloblastoma only has 1 SSDI (biomarker). Brain has 4. Manuals are good, but if your software is not updated, the software will not assign the correct schema.***

***What if this had been a case dx 2022? Still go to the most current version of manuals but pay attention to notes concerning dx date!***

* 1. Version 2.1 (released January 2022)
	2. **Version 3.0 (release January 2023)**
1. SSDI Manual
	1. Version 2.0 (released January 2021)
	2. Version 2.1 (released January 2022)
	3. **Version 3.0 (release January 2023)**

# Quiz 5-Colorectal

1. Site-specific Data Items replaced:
2. AJCC Staging
3. Tumor Markers
4. **Collaborative Stage v2 Site Specific Factors (SSF)**
5. NCDB
6. Increased CEA values **may** indicate:
	1. Biliary obstruction
	2. Colorectal cancer
	3. Alcoholic Hepatitis
	4. Heavy Smoking
	5. **All of the above**
7. When coding multiple pretreatment CEA lab values:
	1. Record first test value prior to treatment
	2. **Record the highest value prior to treatment**
	3. Record normal value prior to treatment
	4. Record lower value prior to treatment
8. CEA is a protein molecule produced in many different cells of the body but associated with gastrointestinal cancers.
	1. **True**
	2. False
9. Circumferential Resection Margin is also known as:
	1. Ileostomy margin
	2. **Mesenteric resection margin**
	3. Lymph node dissection
	4. Colonoscopy
10. When colon is completely encased by the peritoneum, the only relevant margin is:
	1. **Mesenteric margin**
	2. Appendiceal margin
	3. Peritoneal margin
	4. Abdominal soft tissue
11. When margins are positive code:
	1. XX.9
	2. XX.2
	3. **0.0**
	4. XX.0
12. When the margin is described as less than 0.1 mm with no more specific measurement code:
	1. 0.1
	2. **0.0**
	3. XX.0
	4. XX.2
13. For colon biopsy, code Circumferential Resection Margin:
	1. XX.9
	2. 0.0
	3. 0.88
	4. **XX.7**
14. Production of KRAS indicates:
	1. Adverse prognostic factors
	2. Tumor remission
	3. Poor response to anti-EFGR antibody therapy
	4. **A & C**
	5. All of the above
15. KRAS codons are rarely mutated in colorectal cancers.
	1. True
	2. **False**
16. High MSI may indicate:
	1. 5FU chemotherapy is effective treatment
	2. Lynch Syndrome
	3. Unaffected DNA
	4. Tumor tissue with certain non-functioning sections of DNA
	5. All of the above
	6. **B & D**
17. Perineural Invasion is:
	1. Infiltration of regional lymph nodes
	2. **Infiltration of nerves in area of lesion**
	3. Distant Metastasis
	4. Margin status
18. If surgical resection is performed and no mention of the perineural invasion code:
	1. 8
	2. 0
	3. 1
	4. **9**
19. Tumor Deposits are defined as:
	1. Lymph node metastasis
	2. A discrete nodule within the liver
	3. **A discrete nodule in pericolic/perirectal fat**
	4. Distant metastasis
20. Code X9 in SSDI tumor deposit field when:
21. Tumor deposit is not documented in medical record
22. No surgical resection is done
23. Pathology report is not available
24. Tumor deposits are not evaluated
25. **All of the above**
26. Clinical guidelines recommend BRAF mutational analysis for patients with:
	1. In Situ Disease
	2. Local Disease
	3. Regional Disease
	4. **Metastatic Disease**
27. BRAF oncoprotein is involved in transmitting cell growth and proliferation signals from CEA.
	1. True
	2. **False**
28. NRAS is a new data item for cases diagnosed:
	1. 1/1/2018 and forward
	2. 1/1/2020 and forward
	3. **1/1/2021 and forward**
	4. 1/1/2022 and forward
29. NRAS is recorded for:
	1. **All stages**
	2. Metastatic disease only
	3. Assessment of perineural involvement
	4. Local disease only

# Quiz 6- Corpus Uteri

1. If FIGO Stage is provided from clinical & pathological work up:
2. Code the pathologic stage
3. Code the clinical stage
4. **Code most extensive FIGO stage**
5. Code the sage as 99
6. Para-aortic nodes include:
	1. Aortic
	2. Lateral Aortic
	3. Lumbar Aortic
	4. Periaortic
	5. **All of the above**
7. Pelvic Nodes include:
	1. Axillary and mammary
	2. **Iliac and parametrial**
	3. Hilar and Mediastinal
	4. Infraclavicular and Pre-Auricular
8. You can attempt to code FIGO stage based only on T, N, and M
	1. True
	2. **False**
9. For Endometrial Intraepithelial Neoplasia (EIN), the FIGO stage is:
	1. 0
	2. TIS
	3. **97**
	4. 1
10. When no para-aortic lymph nodes are removed, but an aspiration or core biopsy of para-aortic nodes was performed code:
	1. 00
	2. **X6**
	3. X1
	4. X9
11. Where would you find peritoneal cytology reports:
	1. **Pathology Reports**
	2. Op Notes
	3. Radiology Reports
	4. Lab reports
12. Ascites is:
	1. A procedure to remove
	2. A group of lymph nodes
	3. A neoplasm in the stomach
	4. **Excess natural fluid accumulation in the abdominal cavity**
13. If lymph nodes are removed, but no para-aortic lymph nodes are examined code Number of Examined Para-aortic Nodes:
	1. X6
	2. Leave it blank
	3. **00**
	4. X9
	5. X2
14. FIGO provides which of the following for gynecologic malignancies?
	1. Stage criteria for primaries of the cervix
	2. Stage criteria for primaries of the endometrial
	3. Grade criteria for endometrial
	4. **All of the above**
15. The number of positive lymph nodes must ALWAYS be less than or equal to number of nodes examined
	1. **True**
	2. False
16. Involvement of regional and distant lymph nodes is an important prognostic factor:
	1. **True**
	2. False

**Case Scenario:**

70F with Bx-proven FIGO Grade 2 adenoca of the uterus. Pt reported several month hx of vaginal bleeding. A CT scan showed a thickened endometrium that was not present on prior imaging, but no evidence of mets disease. Plan: TAH-BSO.

Path Report #1

**FINAL DIAGNOSIS**
A) Uterine contents, dilation and curettage:  Endometrioid adenocarcinoma (FIGO grade II).

Path Report #2

**FINAL DIAGNOSIS**
A) Uterus, cervix, bilateral tubes and ovaries, hysterectomy and bilateral salpingoophorectomy:
     - Endometrial adenocarcinoma, FIGO grade 2, endometrioid with focal mucinous features, superficial myometrial invasion and areas suspicious for angiolymphatic invasion (extensive knife carryover hinders evaluation)
     - Bilateral fallopian tubes and ovaries negative for neoplasm
     - Myometrium with intramural leiomyoma nodules.
     - See Cancer Summary Data.

B - E) Lymph nodes, as designated, excisions:  Multiple lymph nodes negative for neoplasm including 4 left pelvic, 7 right pelvic, 1 right obturator and 6 left obturator.

**SUMMARY CANCER DATA**
     Specimen type:  Hysterectomy.
     Other organs present:  Right ovary, left ovary, right fallopian tube, Left fallopian tube.

     Specimen integrity:  Intact hysterectomy specimen.
     Chemotherapy and/or radiation therapy prior to surgery:  Unknown/History not provided.
     Characteristics and Extent of Neoplasm:
     Histologic type:  Endometrioid carcinoma, NOS (83803).
     Histologic grade:  FIGO G2:  6% to 50% non-squamous solid growth OR <6% solid with high nuclear grade.
     Tumor size:  Greatest diameter:  3 cm.
     Tumor site (epicenter):  Endometrium of fundus (C54.1).
     Myometrial invasion:  Depth of invasion:  0.7cm / Myometrial thickness:  2cm.
     Lower uterine segment:  Carcinoma invades LUS stroma.
     Cervix and endocervix:  Negative for carcinoma.
     Extra-uterine involvement:  No extra-uterine involvement.
     Venous/lymphatic (large/small vessel) invasion:  Indeterminate.

     Margin Status:  All margins are widely free of carcinoma.
     Lymph Node Status:
     - Pelvic node summary:  Nodes with carcinoma:  0 / Total nodes examined:  18.
     - Para-aortic node summary:  Nodes with carcinoma:  0 / Total nodes examined:  0.
     Minimum Pathologic Stage (AJCC, 8th ed.):
     - Primary tumor (pT):  pT1a:  Tumor limited to endometrium or invades less than one-half of myometrium.
     - Regional lymph nodes (pN):  pN0:  No regional lymph node metastasis.
     Minimum FIGO Stage:  FIGO Stage:  IA:  Tumor limited to endometrium or invades less than half of myometrium.

Path Report #3

**SPECIMEN SOURCE**
A) Pelvic wash

**SPECIMEN DESCRIPTION**
30 ML CLOUDY FLUID IN SPECIMEN CUP WITH "PELVIC WASH" WRITTEN ON LABEL

**CYTOLOGIC IMPRESSION**
Pelvic washing:  Negative for malignancy.  See comment.

|  |
| --- |
| **Number of Positive Para-aortic Nodes: \_X9\_\_****Number of Examined Para-aortic Nodes: \_00\_\_** **Number of Positive Pelvic Nodes: \_00\_\_****Number of Examined Pelvic Nodes: \_18\_\_** |
|  **Peritoneal Cytology: \_0 (Peritoneal cytology/washing negative for malignancy)** |
| **FIGO Stage: \_\_99\_\_** |